IMPORTANCE: Several lines of evidence have linked the endogenous neuromodulator kynurenic acid (KYNA) to schizophrenia. The pathophysiology of schizophrenia is commonly associated with stress, and stress plays a key regulatory role in the first, rate-limiting step of the kynurenine pathway, which produces KYNA. OBJECTIVE: To determine whether the level of KYNA changes following psychological stress and whether this change is associated with stress-related behavior. DESIGN, SETTING, AND PARTICIPANTS: The KYNA level was measured in saliva samples taken at baseline and at 2 times following a laboratory-based psychological stress challenge in 128 participants (64 patients with schizophrenia from outpatient clinics and 64 healthy controls from the community). EXPOSURE: Laboratory-based psychological stress challenge. MAIN OUTCOMES AND MEASURES: Quitting the stressful task early was used as a behavioral marker of distress intolerance. RESULTS: Patients with schizophrenia showed a significantly higher rate of distress intolerance compared with healthy controls (P = .003). Salivary KYNA levels increased significantly between baseline and 20 minutes following the stress task in both patients and controls (mean [SEM], 6.72nM [0.65nM] vs 8.43nM [1.05nM], respectively; P = .007). Patients who were unable to tolerate the stressful tasks and quit early showed significantly higher levels of KYNA than patients who tolerated the psychological stressor (P = .02) or healthy controls (P = .02). In patients with distress intolerance, KYNA elevation significantly correlated with the severity of clinical symptoms (ρ = 0.64; P = .008). CONCLUSIONS AND RELEVANCE: Distress intolerance is more common in patients with schizophrenia. Patients with this behavioral phenotype have elevated salivary KYNA levels. This stress response behavior-linked biomarker may aid heterogeneity reduction in schizophrenia and other stress-related psychiatric conditions.
IMPORTANCE: Several lines of evidence have linked the endogenous neuromodulator kynurenic acid (KYNA) to schizophrenia. The pathophysiology of schizophrenia is commonly associated with stress, and stress plays a key regulatory role in the first, rate-limiting step of the kynurenine pathway, which produces KYNA. OBJECTIVE: To determine whether the level of KYNA changes following psychological stress and whether this change is associated with stress-related behavior. DESIGN, SETTING, AND PARTICIPANTS: The KYNA level was measured in saliva samples taken at baseline and at 2 times following a laboratory-based psychological stress challenge in 128 participants (64 patients with schizophrenia from outpatient clinics and 64 healthy controls from the community). EXPOSURE: Laboratory-based psychological stress challenge. MAIN OUTCOMES AND MEASURES: Quitting the stressful task early was used as a behavioral marker of distress intolerance. RESULTS:Patients with schizophrenia showed a significantly higher rate of distress intolerance compared with healthy controls (P = .003). Salivary KYNA levels increased significantly between baseline and 20 minutes following the stress task in both patients and controls (mean [SEM], 6.72nM [0.65nM] vs 8.43nM [1.05nM], respectively; P = .007). Patients who were unable to tolerate the stressful tasks and quit early showed significantly higher levels of KYNA than patients who tolerated the psychological stressor (P = .02) or healthy controls (P = .02). In patients with distress intolerance, KYNA elevation significantly correlated with the severity of clinical symptoms (ρ = 0.64; P = .008). CONCLUSIONS AND RELEVANCE: Distress intolerance is more common in patients with schizophrenia. Patients with this behavioral phenotype have elevated salivary KYNA levels. This stress response behavior-linked biomarker may aid heterogeneity reduction in schizophrenia and other stress-related psychiatric conditions.
Authors: J A Bosch; H S Brand; T J Ligtenberg; B Bermond; J Hoogstraten; A V Nieuw Amerongen Journal: Psychosom Med Date: 1996 Jul-Aug Impact factor: 4.312
Authors: L K Nilsson; K R Linderholm; G Engberg; L Paulson; K Blennow; L H Lindström; C Nordin; A Karanti; P Persson; S Erhardt Journal: Schizophr Res Date: 2005-08-25 Impact factor: 4.939
Authors: Damian Kuc; Mansur Rahnama; Tomasz Tomaszewski; Wojciech Rzeski; Katarzyna Wejksza; Teresa Urbanik-Sypniewska; Jolanta Parada-Turska; Marian Wielosz; Waldemar A Turski Journal: Pharmacol Rep Date: 2006 May-Jun Impact factor: 3.024
Authors: Bridget J Shovestul; Matthew Glassman; Laura M Rowland; Robert P McMahon; Fang Liu; Deanna L Kelly Journal: Schizophr Res Date: 2017-01-09 Impact factor: 4.939
Authors: Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2017-07-01 Impact factor: 9.306
Authors: Krista M Wisner; Joshua Chiappelli; Anya Savransky; Feven Fisseha; Laura M Rowland; Peter Kochunov; L Elliot Hong Journal: Brain Imaging Behav Date: 2020-04 Impact factor: 3.978
Authors: Joshua Chiappelli; Qiaoyun Shi; Priyadurga Kodi; Anya Savransky; Peter Kochunov; Laura M Rowland; Katie L Nugent; L Elliot Hong Journal: Psychoneuroendocrinology Date: 2015-09-12 Impact factor: 4.905
Authors: Dwight Dickinson; Danielle N Pratt; Evan J Giangrande; MeiLin Grunnagle; Jennifer Orel; Daniel R Weinberger; Joseph H Callicott; Karen F Berman Journal: Schizophr Bull Date: 2018-01-13 Impact factor: 9.306
Authors: Joshua Chiappelli; Laura M Rowland; Francesca M Notarangelo; S Andrea Wijtenburg; Marian A R Thomas; Ana Pocivavsek; Aaron Jones; Krista Wisner; Peter Kochunov; Robert Schwarcz; L Elliot Hong Journal: Neuropsychopharmacology Date: 2018-04-18 Impact factor: 7.853